FOXM1 and prostate carcinoma: A total of nine cancer cell lines were subjected to asciminib treatment, and remarkably impaired stability of FOXM1 and decreased expression were observed in most of these cancer cell lines including prostatic cancer LNCaP, lung cancer A549, hepatocellular carcinoma HuH7, pancreatic cancer MIA PaCa-2, and breast cancer BT-20 and SK-BR-3, whereas asciminib treatment could not significant impact FOXM1 expression in neuroblastoma SH-SY5Y, ovarian cancer SK-OV-3 and breast cancer MDA-MB-231 cell lines (Supplementary Fig. S8).